InflaRx

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

APTO

AREB

CISS

CVKD

IFRX

Intelligent Bio Solutions Inc. - Common Stock

INBS

INTC

JAGX

KLAC

ONCO

REVB

TCBP

TELL

VMAR

WLGS

YIBO

Shares of  Tellurian Inc. (NASDAQ: TELL) shares rose sharply in pre-market trading following a report suggesting the company hired Lazard to explore a possible sale.

Tellurian shares jumped 16.3% to $0.6050 in pre-market trading

Why Tellurian Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

AAPL

ARBB

BDRX

BILL

CYTO

DMTK

DOCN

EIGR

EZGO

FOXF

FTNT

HIPO

INSG

INVO

MCAF

NVOS

RVSN

SECO

Gainers

Altamira Therapeutics Ltd (NASDAQ: CYTO) shares surged 54.1% to $0.25 in pre-market trading after gaining 5% on Thursday.

Why DigitalOcean Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

AMTD

APRN

AUUD

CYXT

DATS

FRZA

IFBD

KDNY

MCOM

MDGS

Airspan Networks Holdings Inc. Common Stock

MIMO

ONCR

SIEN

TENX

Gainers


	Auddia Inc.  (NASDAQ: AUUD) shares rose 103.2% to $0.8809 in pre-market trading after gaining around 9% on Friday.


Why Oncorus Shares Are Trading Lower By 25%; Here Are 20 Stocks Moving Premarket

InflaRx NV

Press Releases

General

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

InflaRx Announces Participation in January Events in San Francisco

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference

Financing

InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants

InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Infinitum: Pioneering Quantum-Proof Blockchain Solutions to Transform Finance

InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

Health Care

InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

HC Wainwright & Co.

Raymond James

Credit Suisse

SVB Leerink

Comments

InflaRx

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga